FEZF2, a novel 3p14 tumor suppressor gene, represses oncogene EZH2 and MDM2 expression and is frequently methylated in nasopharyngeal carcinoma

Carcinogenesis

Volumn 34, Issue 9, 2013, Pages 1984-1993

  Shu, Xing sheng ^a   Li, Lili ^a   Ji, Mingfang ^b   Cheng, Yingduan ^a   Ying, Jianming ^a   Fan, Yichao ^a   Zhong, Lan ^a   Liu, Xiaodong ^b   Tsao, Sai Wah ^c   Chan, Anthony T C ^a   Tao, Qian ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b SUN YAT SEN UNIVERSITY   (China)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; FEZ FAMILY ZINC FINGER 2 PROTEIN; HISTONE DEACETYLASE; PROTEIN MDM2; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN;

ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BRAIN; CANCER CELL CULTURE; CELL CLONING; CELL IMMORTALIZATION; CLONOGENESIS; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DOWN REGULATION; EPITHELIUM CELL; FETUS; FEZF2 GENE; G2 PHASE CELL CYCLE CHECKPOINT; GENE DELETION; GENE EXPRESSION; GENE IDENTIFICATION; GENE INACTIVATION; GENE OVEREXPRESSION; GENE REPRESSION; GENE SILENCING; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; M PHASE CELL CYCLE CHECKPOINT; MALE; MIGRATION INHIBITION; MOUSE; NASOPHARYNX; NASOPHARYNX CARCINOMA; NONHUMAN; ONCOGENE; ONCOGENE EZH2; ONCOGENE MDM2; OVARY; PRIORITY JOURNAL; PROMOTER REGION; REPRESSOR GENE; RESPIRATORY EPITHELIUM; TESTIS; TUMOR SUPPRESSOR GENE;

CELL LINE, TUMOR; DNA METHYLATION; EPITHELIAL CELLS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HEK293 CELLS; HUMANS; NASOPHARYNGEAL NEOPLASMS; NASOPHARYNX; POLYCOMB REPRESSIVE COMPLEX 2; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-MDM2; TRANSCRIPTION FACTORS;

EID: 84886997326     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgt165     Document Type: Article

References (48)

1. Balmain, A. et al. (2003) The genetics and genomics of cancer. Nat. Genet., 33, 238-244.
2. Baylin, S.B. et al. (2006) Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat. Rev. Cancer, 6, 107-116.
3. Vogelstein, B. et al. (2004) Cancer genes and the pathways they control. Nat. Med., 10, 789-799.
4. Tao, Q. et al. (2007) Nasopharyngeal carcinoma: molecular pathogenesis and therapeutic developments. Expert Rev. Mol. Med., 9, 1-24.
5. Solimini, N.L. et al. (2012) Recurrent hemizygous deletions in cancers may optimize proliferative potential. Science, 337, 104-109.
6. Zabarovsky, E.R. et al. (2002) Tumor suppressor genes on chromosome 3p involved in the pathogenesis of lung and other cancers. Oncogene, 21, 6915-6935.
7. Ogasawara, S. et al. (1995) Frequent microsatellite alterations on chromosome 3p in esophageal squamous cell carcinoma. Cancer Res., 55, 891-894.
8. Martinez, A. et al. (2001) Chromosome 3p allele loss in early invasive breast cancer: detailed mapping and association with clinicopathological features. Mol. Pathol., 54, 300-306.
9. Ko, J.Y. et al. (2002) Definition of three minimal deleted regions by comprehensive allelotyping and mutational screening of FHIT, p16(INK4A), and p19(ARF) genes in nasopharyngeal carcinoma. Cancer, 94, 1987-1996.
10. Cheung, A.K. et al. (2008) Functional analysis of a cell cycle-associated, tumor-suppressive gene, protein tyrosine phosphatase receptor type G, in nasopharyngeal carcinoma. Cancer Res., 68, 8137-8145.
11. Lo, P.H. et al. (2010) Extracellular protease ADAMTS9 suppresses esophageal and nasopharyngeal carcinoma tumor formation by inhibiting angiogenesis. Cancer Res., 70, 5567-5576.
12. Lo, K.W. et al. (2001) High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma. Cancer Res., 61, 3877-3881.
13. Wong, T.S. et al. (2004) Quantitative plasma hypermethylated DNA markers of undifferentiated nasopharyngeal carcinoma. Clin. Cancer Res., 10, 2401-2406.
14. Qiu, G.H. et al. (2004) The candidate tumor suppressor gene BLU, located at the commonly deleted region 3p21.3, is an E2F-regulated, stress-responsive gene and inactivated by both epigenetic and genetic mechanisms in nasopharyngeal carcinoma. Oncogene, 23, 4793-4806.
15. Hu, X.T. et al. (2009) Phospholipase C delta 1 is a novel 3p22.3 tumor suppressor involved in cytoskeleton organization, with its epigenetic silencing correlated with high-stage gastric cancer. Oncogene, 28, 2466-2475.
16. Ying, J. et al. (2009) DLEC1 is a functional 3p22.3 tumour suppressor silenced by promoter CpG methylation in colon and gastric cancers. Br. J. Cancer, 100, 663-669.
17. Matsuo-Takasaki, M. et al. (2000) Cloning and expression of a novel zinc finger gene, Fez, transcribed in the forebrain of Xenopus and mouse embryos. Mech. Dev., 93, 201-204.
18. Levkowitz, G. et al. (2003) Zinc finger protein too few controls the development of monoaminergic neurons. Nat. Neurosci., 6, 28-33.
19. Yang, Z. et al. (2001) A zebrafish forebrain-specific zinc finger gene can induce ectopic dlx2 and dlx6 expression. Dev. Biol., 231, 138-148.
20. Rouaux, C. et al. (2010) Fezf2 directs the differentiation of corticofugal neurons from striatal progenitors in vivo. Nat. Neurosci., 13, 1345-1347.
21. Shimizu, T. et al. (2010) Zinc finger genes Fezf1 and Fezf2 control neuronal differentiation by repressing Hes5 expression in the forebrain. Development, 137, 1875-1885.
22. Chen, J.G. et al. (2005) Zfp312 is required for subcortical axonal projections and dendritic morphology of deep-layer pyramidal neurons of the cerebral cortex. Proc. Natl Acad. Sci. USA, 102, 17792-17797.
23. Chen, B. et al. (2005) Fezl regulates the differentiation and axon targeting of layer 5 subcortical projection neurons in cerebral cortex. Proc. Natl Acad. Sci. USA, 102, 17184-17189.
24. Shim, S. et al. (2012) Cis-regulatory control of corticospinal system development and evolution. Nature, 486, 74-79.
25. Shimizu, T. et al. (2009) Formation and patterning of the forebrain and olfactory system by zinc-finger genes Fezf1 and Fezf2. Dev. Growth Differ., 51, 221-231.
26. Song, I.S. et al. (2009) Human ZNF312b promotes the progression of gastric cancer by transcriptional activation of the K-ras gene. Cancer Res., 69, 3131-3139.
27. Cui, Y. et al. (2008) OPCML is a broad tumor suppressor for multiple carcinomas and lymphomas with frequently epigenetic inactivation. PLoS One, 3, e2990.
28. Cheng, Y. et al. (2010) KRAB zinc finger protein ZNF382 is a proapoptotic tumor suppressor that represses multiple oncogenes and is commonly silenced in multiple carcinomas. Cancer Res., 70, 6516-6526.
29. Tsao, S.W. et al. (2002) Establishment of two immortalized nasopharyngeal epithelial cell lines using SV40 large T and HPV16E6/E7 viral oncogenes. Biochim. Biophys. Acta, 1590, 150-158.
30. Feng, P. et al. (2000) Expression of Epstein-Barr virus lytic gene BRLF1 in nasopharyngeal carcinoma: potential use in diagnosis. J. Gen. Virol., 81(Pt 10), 2417-2423.
31. Shu, X.S. et al. (2011) The epigenetic modifier PRDM5 functions as a tumor suppressor through modulating WNT/β-catenin signaling and is frequently silenced in multiple tumors. PLoS One, 6, e27346.
32. Ying, J. et al. (2006) Functional epigenetics identifies a protocadherin PCDH10 as a candidate tumor suppressor for nasopharyngeal, esophageal and multiple other carcinomas with frequent methylation. Oncogene, 25, 1070-1080.
33. Tao, Q. et al. (2002) Defective de novo methylation of viral and cellular DNA sequences in ICF syndrome cells. Hum. Mol. Genet., 11, 2091-2102.
34. Li, L. et al. (2010) The tumor suppressor UCHL1 forms a complex with p53/MDM2/ARF to promote p53 signaling and is frequently silenced in nasopharyngeal carcinoma. Clin. Cancer Res., 16, 2949-2958.
35. Li, L. et al. (2011) The human cadherin 11 is a pro-apoptotic tumor suppressor modulating cell stemness through Wnt/beta-catenin signaling and silenced in common carcinomas. Oncogene, 23, 3901-3912.
36. Chen, L. et al. (2011) Genomic selection identifies vertebrate transcription factor Fezf2 binding sites and target genes. J. Biol. Chem., 286, 18641-18649.
37. Hui, A.B. et al. (2005) Array-based comparative genomic hybridization analysis identified cyclin D1 as a target oncogene at 11q13.3 in nasopharyngeal carcinoma. Cancer Res., 65, 8125-8133.
38. Sozzi, G. et al. (1996) The FHIT gene 3p14.2 is abnormal in lung cancer. Cell, 85, 17-26.
39. Huebner, K. et al. (2003) Cancer and the FRA3B/FHIT fragile locus: it's a HIT. Br. J. Cancer, 88, 1501-1506.
40. Loyo, M. et al. (2011) A survey of methylated candidate tumor suppressor genes in nasopharyngeal carcinoma. Int. J. Cancer, 128, 1393-1403.
41. Della Peruta, M. et al. (2010) Protein tyrosine phosphatase receptor type {gamma} is a functional tumor suppressor gene specifically downregulated in chronic myeloid leukemia. Cancer Res., 70, 8896-8906.
42. Shu, S.T. et al. (2010) Function and regulatory mechanisms of the candidate tumor suppressor receptor protein tyrosine phosphatase gamma (PTPRG) in breast cancer cells. Anticancer Res., 30, 1937-1946.
43. Sheu, J.J. et al. (2009) Chromosome 3p12.3-p14.2 and 3q26.2-q26.32 are genomic markers for prognosis of advanced nasopharyngeal carcinoma. Cancer Epidemiol. Biomarkers Prev., 18, 2709-2716.
44. Jones, P.A. et al. (2002) The fundamental role of epigenetic events in cancer. Nat. Rev. Genet., 3, 415-428.
45. Robertson, K.D. (2005) DNA methylation and human disease. Nat. Rev. Genet., 6, 597-610.
46. Shu, X.S. et al. (2012) Chromatin regulators with tumor suppressor properties and their alterations in human cancers. Epigenomics, 4, 537-549.
47. Rhodes, D.R. et al. (2004) ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia, 6, 1-6.
48. Song, I.S. et al. (2011) Human ZNF312b oncogene is regulated by Sp1 binding to its promoter region through DNA demethylation and histone acetylation in gastric cancer. Int. J. Cancer, 129, 2124-2133.